Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019693 (HIV)
 170,526 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This study determines the prevalence of Mycobacterium tuberculosis (TB) infection and the incidence among HIV infected and uninfected women in urban Rwanda. The sample population includes 460 HIV-positive women and 998 HIV-negative women who were recruited from pediatric and prenatal care clinics at the Centre Hospitalier de Kigali. The sample is considered representative of childbearing women from the capital city. Initial interviews were conducted in 1988 and followed-up in 1990. HIV-1 diagnosis was determined on the basis of enzyme immunoassay and western blot tests or indirect immunofluorescence that showed reactivity to both a core protein and an envelope protein. A positive tuberculin test was defined as induration of 10 mm or more. Routine visits were made every 6 months. Comparisons were made between women who were HIV positive at their first HIV test (250 women), women who were negative at their first test but seroconverted between the first HIV test and the TB test 3 years later (80 women), and women who were HIV negative at the time of TB testing (687). 55% of HIV-negative women had positive tests with induration of more than 10 mm. 25% of HIV-positive women and 66% of HIV-negative women had TB tests with over 5 mm induration. 31% of HIV-positive women and 70% of HIV-negative women had induration of over 2 mm. 77% of women had TB vaccine scars. Prevalence of a positive test was significantly higher in the HIV-negative vaccinated group than in the nonvaccinated group. The proportion with low white cell counts, low lymphocyte counts, and high sedimentation rates was higher among HIV-positive women than HIV-negative women. During the 2-year follow-up period, 20 of the 401 HIV-positive women and 2 of the 917 HIV-negative women were diagnosed with TB. The risk ratio was 22.9. The incidence of TB was 3 times higher among women who had been infected with HIV at least 18 months than among women who had been infected less than 18 months. Low income and low body mass were associated with an increased risk of TB. 9 out of 17 HIV-infected women with TB had negative TB tests.
 ...
PMID:Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. 145 59

To examine the possible influence of AIDS and HIV infection on the epidemiology of tuberculosis in Europe and worldwide in the coming decades an analysis of the available data on the two diseases and on the transmission of the two infections in relation to the demographic structure of the population was conducted, including projections for up to the year 2025. Globally, the effects of the AIDS pandemic on the tuberculosis situation will probably be very serious, adding some 1.5 million new cases of tuberculosis annually by the year 2025 as a result of HIV infection. However, this effect for Europe in the year 2025 may be in the range of 15,000 additional cases only. The main factor determining the scale of aggravation of Tb is the age structure of the population infected, or at risk of being infected, with tubercle bacilli and HIV. Although the influence of HIV infection on tuberculosis in Europe may not be very high due to the fact that HIV infection involves mainly younger age groups it may, however, substantially postpone the elimination of tuberculosis from Europe. Therefore it seems necessary to monitor constantly all the changes in the epidemiological situation of both tuberculosis and AIDS/HIV.
 ...
PMID:Tuberculosis and AIDS: European and worldwide perspectives. 146 11

Respiratory infections are particularly frequent in HIV infection. They depend upon the degree of immunodeficiency, the geographical region and a possible prophylaxis. Bronchopneumopathies caused by pyogenic organisms (notably pneumococci) appear when the number of T4 lymphocytes is little reduced. Pulmonary tuberculosis, particularly frequent in Africans and Haitians, occurs in patients with moderate immunodeficiency (T4 between 200 and 300/mm3). HIV infections modify the epidemiology of tuberculosis in Africa, but also in the USA and probably in Europe. Despite a well-established prophylaxis, pneumocystosis, which develops when the number of T4 cells falls below 200/mm3, is the opportunistic pathology which in most cases points to AIDS in the USA and in France. Atypical mycobacterial infections (Mycobacterium avium complex) and CMV infections occur at a late stage of the disease in patients with severe immunodeficiency. Noticeable advances have recently been made in the treatment of these complications.
 ...
PMID:[Infectious respiratory complications of AIDS]. 146 66

95% of tuberculosis (TB) cases in the world live in developing countries. HIV infection greatly increases the risk of developing active TB among those with latent Mycobacterium tuberculosis infection. Thus researchers have used data from existing research to develop a mathematical model to gauge the increase in TB incidence in developing countries while considering rising HIV prevalence among adults. They look at 2 groups with sizable differences in risk of acquiring TB: adults with both HIV and M. tuberculosis infections and all other adults. The researchers plot the expected increase in TB incidence and percentage of TB cases that also have HIV infection against HIV prevalence. According to the model, when the prevalence of HIV infection hits 13% of adults in developing countries, the number of new TB cases doubles. Most of this increase will occur in areas that already lack diagnostic services, drugs, hospital beds, and other needed supplies. TB chemoprophylaxis treatment of HIV-positive people could result in a lower increase in TB incidence, however. WHO has set a goal of 50% reduction in TB incidence by 2002. Public health officials could use this model to plan TB control programs to bring about a reduction in the increase. Even though TB control programs can help stem the projected increase, it will be very difficult for developing countries with high HIV prevalence to hold back the projected rise in TB incidence. Developing countries must take considerable appropriate action soon to prevent doubling of TB incidence as HIV prevalence nears 13% of adults.
 ...
PMID:Tuberculosis incidence in developing countries with high prevalence of HIV infection. 146 53

In 1990, among pregnant women .1% tested positive for HIV antibodies in Amsterdam compared to 24.5% in Lusaka, Zambia. During 1990 and 1991 data were collected from 231 patients fulfilling the WHO clinical criteria for the diagnosis of AIDS in 3 hospitals of Sesheke, a rural Zambian district. 46.3% of the group was male and 53.7% was female, and the mean age of women was significantly lower than that of men (25.2 vs. 31.1 years, p 0.001). A total of 185 patients could be tested for HIV-1 antibodies using ELISA-Welcozyme and HIVCECK-Du Pont. There were 141 (81.6%) positive results, 19 (10.3%) negative results, and in 15 (8.1%) cases the outcome was not clear. Seroprevalence figures for HIV-1 in the same period were 16% for blood donors and 41% for patients attending the clinic for sexually transmitted diseases. Most patients with AIDS in Sesheke district present with a wasting syndrome, and in these cases, tuberculosis (TB), whose incidence has increased dramatically, has to be excluded. Loss of more than 10% of body weight was the most common symptom followed by chronic cough lasting for more than 1 month, fever persisting for more than 1 month, and chronic diarrhea lasting for more than 1 more. Chronic coughing was more frequent among adults than among children (P 0.001). Weight loss, chronic diarrhea, persistent coughing, generalized lymphadenopathy, generalized dermatitis, and oropharyngeal candidiasis occurred among both adults and children equally often. Only 4 patients (18%) and extrapulmonary TB in 10 patients (4%). In the district there was no registration system for the dead and the follow-up of AIDS patients were not organized well, but as of January 1, 1992, from hospital records it was established that 74 patients out of the 231 studied were decreased. The outlook for the population in Sesheke and Zambia is dim in light of the current high seroprevalence rate.
 ...
PMID:[AIDS in a Zambian district]. 147 Feb 44

In the period 1980-1985, we treated 1641 patients for tuberculosis of whom two were known to be intravenous drug users (IVDU) and none had HIV infection. Of the next 1000 patients treated for tuberculosis (January 1986-December 1989), six were HIV-negative intravenous drug users (IVDU), 18 patients were HIV-positive (12 IVDU; six homosexual/bisexual). Statistical analysis (chi 2) showed a numerically small but statistically significant (P < 0.00001, d.f. = 1, chi 2 = 20.38) increase in intravenous drug users with a diagnosis of tuberculosis. The HIV-positive patients who completed treatment responded well to anti-tuberculous drugs. The importance of tuberculosis in the context of HIV infection is that it is preventable, treatable and is the only bacterial infection to which HIV subjects are prone which can be readily transmitted to a non-HIV infected subject.
 ...
PMID:AIDS, i.v. drug use and mycobacterial disease: the Dublin experience. 147 Jul 6

Since 1985 there has been an 18% increase in the number of cases of tuberculosis nationally. Even more alarming is the increasing incidence of multidrug-resistant tuberculosis which presents a serious public health problem, particularly for HIV-infected patients.
 ...
PMID:Resurgence of tuberculosis. 147 34

In spite of alarming reports from third world and industrialized countries, no increase in the incidence of tuberculosis has been seen in Switzerland. This is mainly attributable to the consistently performed initial treatment with a multiple-drug combination and the good compliance of our patients. In Switzerland the diagnosis of tuberculosis is difficult, because of its low incidence (1990: 1229 reported cases), as well as its nonspecific initial symptoms. Screening tests are only indicated in high risk-populations with direct contact to infectious tuberculosis cases, inhabitants of centres for homeless or immigrants, foreign workers and HIV-positives. The fast introduction of the gene amplification method with the polymerase chain reaction (PCR) would allow bacteriologic diagnosis within 48 hours. This would be of great practical relevance, allowing a quicker initiation of therapy and with that, a decrease of infection risk for physicians and medical staff, especially in endoscopy-rooms, emergency- and intensive care units. In Switzerland the multiple-drug resistance of mycobacteria (against insoniazid, rifampicin and other antimycobacterial agents) is seen only rarely (0.7 to 1.3% of cases). In patients with origin from countries with frequent drug-resistance to isoniazid and even more in case of suspected multiple drug-resistance or high initial bacterial count (cavernous tuberculosis), an initial combination therapy with four different antimycobacterial drugs should be applied, until the result of the susceptibility-tests is available.
 ...
PMID:[The difficult diagnosis of tuberculosis]. 147 58

An estimated 2.8 million people in Africa have dual infections with tuberculosis and human immunodeficiency virus (HIV). Because of the increasing numbers of cases of tuberculosis as a consequence of the HIV epidemic, chemoprophylaxis may become a cost effective tuberculosis control measure in high prevalence countries. Although isoniazid (INH) is the only drug evaluated in controlled trials of preventive tuberculosis therapy, studies are now under way to determine the efficacy of INH and other drugs, including rifampicin and pyrazinamide, in preventing tuberculosis reactivation in persons with HIV infection. If chemoprophylaxis is effective in persons with dual infection, further studies will be required to determine whether chemoprophylaxis is cost effective for tuberculosis prevention and control and whether it is feasible to introduce it as a community control measure.
 ...
PMID:Aspects of tuberculosis in Africa. 1. Tuberculosis in Africa in the AIDS era--the role of chemoprophylaxis. 823 13

Optimum treatment of tuberculosis in persons with human immunodeficiency virus (HIV) infection is still being defined. Tuberculosis treatment failure in an HIV-infected patient is described and 10 similar cases from the medical literature are reviewed to search for common patterns associated with an adverse outcome of therapy in this setting. Six patients were poorly compliant. In nine patients, the subsequent episode of tuberculosis was disseminated or extrapulmonary; in four the central nervous system was involved. In five patients, a problem with rifampin usage was encountered: Three had rifampin-resistant Mycobacterium tuberculosis, one experienced an adverse reaction to rifampin, leading to withdrawal from the regimen after 1 week, and one was receiving a drug that may interfere with rifampin's antimycobacterial effect. This case report and literature review suggest that particular attention should be directed toward ensuring that patients with HIV infection comply with treatment of tuberculosis. For the majority of patients, the already stretched resources available for the treatment of tuberculosis and HIV infection should be devoted to compliance enhancement rather than to more prolonged or intensive drug regimens. However, it should be emphasized that patients with disseminated tuberculosis or central nervous system disease and those who are not able to receive rifampin because of drug resistance or an adverse reaction should be managed individually.
 ...
PMID:Failure of therapy for tuberculosis in human immunodeficiency virus infection. 147 56


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>